Adjuvant oxaliplatin with S-1 (SOX) versus S-1 for stage II-III gastric cancer (CAPITAL): A randomized, open-label, phase 3 trial.
- DOI
- 10.1016/j.medj.2026.101258
- Published
- 2026 Sep 11
- Container
- Med (New York, N.Y.)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.medj.2026.101258,
title = {Adjuvant oxaliplatin with S-1 (SOX) versus S-1 for stage II-III gastric cancer (CAPITAL): A randomized, open-label, phase 3 trial.},
author = {Nie RC and Chen S and Wan J and Sun XW and Hong WQ and Wei HB and Wang W and Zhang WB and Zhao Y and Zhang WB and Chen JS and Wu ZG and Mai C and Feng CZ and Yuan SQ and Wang W and Qiu HB and Liang Y and Guan YX and Chen YM and Liu WW and Ding C and Peng JS and Chen YB and Zhou ZW and Li YF},
year = {2026},
journal = {Med (New York, N.Y.)},
doi = {10.1016/j.medj.2026.101258},
url = {https://doi.org/10.1016/j.medj.2026.101258}
}RIS
TY - JOUR TI - Adjuvant oxaliplatin with S-1 (SOX) versus S-1 for stage II-III gastric cancer (CAPITAL): A randomized, open-label, phase 3 trial. AU - Nie RC AU - Chen S AU - Wan J AU - Sun XW AU - Hong WQ AU - Wei HB AU - Wang W AU - Zhang WB AU - Zhao Y AU - Zhang WB AU - Chen JS AU - Wu ZG AU - Mai C AU - Feng CZ AU - Yuan SQ AU - Wang W AU - Qiu HB AU - Liang Y AU - Guan YX AU - Chen YM AU - Liu WW AU - Ding C AU - Peng JS AU - Chen YB AU - Zhou ZW AU - Li YF PY - 2026 JO - Med (New York, N.Y.) DO - 10.1016/j.medj.2026.101258 UR - https://doi.org/10.1016/j.medj.2026.101258 ER -
APA
RC, N., S, C., J, W., XW, S., WQ, H., HB, W., W, W., WB, Z., Y, Z., WB, Z., JS, C., ZG, W., C, M., CZ, F., SQ, Y., W, W., HB, Q., Y, L., YX, G., YM, C., WW, L., C, D., JS, P., YB, C., ZW, Z., & YF, L. (2026). Adjuvant oxaliplatin with S-1 (SOX) versus S-1 for stage II-III gastric cancer (CAPITAL): A randomized, open-label, phase 3 trial.. Med (New York, N.Y.). https://doi.org/10.1016/j.medj.2026.101258
Source records
- pubmed · retrieved 2026-09-25T13:58:28.255Z